Overview

* NeoGenomics ( NEO ) Q2 revenue up 10% to $181 mln, missing analyst expectations

* Net loss increased 142% to $45 mln due to $20 mln impairment charges

* Completed Pathline acquisition in April, boosting clinical revenue growth

Outlook

* NeoGenomics ( NEO ) sees 2025 revenue between $720 mln and $726 mln

* Company expects 2025 net loss between $108 mln and $116 mln

* NeoGenomics ( NEO ) anticipates 2025 adjusted EBITDA of $41 mln to $44 mln

* Company preparing for the commercial launch of PanTracer Liquid Biopsy

Result Drivers

* CLINICAL REVENUE - Clinical revenue grew 16% due to improved average unit price, record volumes, and 23% growth in NGS, per CEO Tony Zook; Clinical revenue grew 13% excluding Pathline

* PHARMA REVENUE PRESSURE - Continued pressure in pharma revenue affected overall performance, beyond initial assumptions

* LAUNCH DELAY - Delay in commercial launch of PanTracer Liquid Biopsy impacted expected NGS revenue

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Miss $181 mln $182.70

Revenue mln (14

Analysts

)

Q2 -$3.60

Adjusted mln

Net

Income

Q2 Net -$45 mln

Income

Q2 $10.70

Adjusted mln

EBITDA

Q2 Gross $77 mln

Profit

Q2 $125 mln

Operatin

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 7 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the healthcare facilities & services peer group is "buy"

* Wall Street's median 12-month price target for Neogenomics Inc ( NEO ) is $12.00, about 46.2% above its July 28 closing price of $6.46

* The stock recently traded at 27 times the next 12-month earnings vs. a P/E of 44 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)